Dalbavancin is under clinical development by AbbVie and currently in Phase III for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections. According to GlobalData, Phase III drugs for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections have an 11% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Dalbavancin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Dalbavancin overview
Dalbavancin (Dalvance, Xydalba) is a second generation, semi-synthetic lipoglycopeptide. It is formulated as injection powder for concentrate solution for intravenous route of administration. Dalbavancin is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible Gram-positive bacteria, including infections caused by methicillin-resistant Staphylococcus aureus (MRSA).
Dalbavancin is under development for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections, acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible Gram-positive bacteria, including infections caused by methicillin-resistant Staphylococcus aureus (MRSA) in pediatric patients.
It was also under development for the treatment of community-acquired pneumonia, infective endocarditis, bacteremia, catheter-related bloodstream infections (CRBSIs), acute hematogenous osteomyelitis of the long bones known or suspected to be due to gram-positive organisms in pediatric subjects, osteomyelitis in adult and Neisseria gonorrhoeae infections.
AbbVie overview
AbbVie is a specialty biopharmaceutical company, which discovers, develops, manufactures, and commercializes drugs for the treatment of chronic and complex diseases. Its drugs are indicated for the treatment of metabolic and rheumatological diseases, neurological disorders, skin diseases, rheumatoid arthritis, pain related to endometriosis, pediatric Crohn’s disease, cancer, and other serious health conditions. AbbVie is also advancing its pipeline programs for the treatment of Crohn’s disease, Parkinson’s disease, viral diseases, wet AMD, various cancers, neurological disorders, aesthetics, and other autoimmune diseases. The company markets its products directly to wholesalers, distributors, healthcare facilities, government agencies, specialty pharmacies and independent retailers through its own distribution centers and public warehouses worldwide. AbbVie is headquartered in North Chicago, Illinois, the US.
For a complete picture of Dalbavancin’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
